HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links
Discovering New Therapeutics Uses for Existing Molecules

2017 Industry-Provided Assets

Assets in this table are alphabetized by mechanism of action. These compounds and biologics have undergone significant pre-clinical and safety testing in humans.


2017 Table of Assets for Adult Indications

Code Number & Link to More Information

Mechanism
of Action

Original Development Indication(s)

Route of Administration Formulation Available
(CNS Penetrant+)

AZD4017 (PDF - 130KB)

11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor

Diabetes

Oral
(Low)

AZD5363 (PDF - 178KB)

AKT serine/threonine protein kinase (also known as protein kinase B alpha) inhibitor

Solid and hematological malignancies

Oral
(Low)

AZD6738 (PDF - 139KB)

Ataxia telangiectasia and Rad3 related (ATR) serine/threonine protein kinase inhibitor

Chronic lymphocytic leukemia

Oral
(Unknown)

AZD5069 (PDF - 73KB)

Chemokine (C-X-C motif) receptor 2 (CXCR2) antagonist

Asthma

Oral
(Unknown)

JNJ-39269646 (PDF - 34KB)

Fast dissociating D2/D3/5-HT6 antagonist

Schizophrenia
Bipolar depression

Oral
(Yes)

AZD4547 (PDF - 97KB)

Fibroblast growth factor receptor (FGFR) tyrosine kinase family inhibitor

Solid tumors

Oral
(Low)

AZD7325 (PDF - 117KB)
Bavisant

Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABA Aα2,3) positive modulator

General anxiety disorder

Oral
(Yes)

AZD3355 (PDF - 100KB)
Lesogaberan

Gamma-aminobutyric acid receptor B (GABA B) agonist

Gastroesophageal reflux disease

Oral
(Low)

AZD1656 (PDF - 121KB)

Glucokinase (GK; hexokinase 4) activator

Diabetes

Oral
(Low)

AZD5213 (PDF - 135KB)

Histamine receptor 3 (H3) antagonist (inverse agonist)

Cognition
Daytime sleepiness
Tourette syndrome

Oral
(Yes)

AZD2014 (PDF - 104KB)
Vistuserib

Mammalian target of rapamycin (mTOR) serine/threonine kinase (dual TORC1 and TORC2) inhibitor

Solid tumors

Oral
(Low)

AZD3241 (PDF - 121KB)

Myeloperoxidase (MPO) inhibitor

Parkinson’s disease
Multiple system atrophy

Oral
(Yes)

AZD5904 (PDF - 65KB)

Myeloperoxidase (MPO) inhibitor

Chronic obstructive pulmonary disease
Multiple sclerosis

Oral
(Low)

AZD0328 (PDF - 97KB)

Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist

Cognitive impairment

Oral
(Yes)

JNJ-39393406 (PDF - 65KB)

Nicotinic acetylcholine receptor, alpha 7 (α7 nAChR) positive allosteric modulator

Cognitive impairment in schizophrenia

Oral
(Yes)

AZD9668 (PDF - 63KB)
Alvelestat

Neutrophil elastase (NE) inhibitor

Chronic obstructive pulmonary disease
Bronchiectasis
Cystic fibrosis

Oral
(Low)

JNJ-19385899 (PDF - 72KB)

Nociceptin/orphanin-FQ receptor (NOP) agonist

Anxiety
Depression

Oral
(Yes)

AZD9150 (PDF - 85KB)

Signal transducer and activator of transcription 3 (STAT3) antisense

Hepatocellular carcinoma

Intravenous
(Low)

AZD0530 (PDF - 111KB)
Saracatinib

Src tyrosine kinase family inhibitor

Solid tumors

Oral
(Yes)

AZD1775 (PDF - 104KB)

WEE1 G2 checkpoint kinase inhibitor

Advanced solid tumors

Oral
(Unknown)

+CNS penetrant: Yes, no,maybe, low or unknown.

2017 Table of Assets for Pediatric Indications

Code Number & Link to More Information

Mechanism
of Action

Original Development Indication(s)

Route of Administration Formulation Available
(CNS Penetrant+)

AZD7325 (PDF - 117KB)
Bavisant

Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABA Aα2,3) positive modulator

General anxiety disorder

Oral
(Yes)

AZD3355 (PDF - 100KB)
Lesogaberan

Gamma-aminobutyric acid receptor B (GABA B) agonist

Gastroesophageal reflux disease

Oral
(Low)

AZD1656 (PDF - 121KB)

Glucokinase (GK; hexokinase 4) activator

Diabetes

Oral
(Low)

AZD5213 (PDF - 135KB)

Histamine receptor 3 (H3) antagonist (inverse agonist)

Cognition
Daytime sleepiness
Tourette syndrome

Oral
(Yes)

AZD9668 (PDF - 63KB)
Alvelestat

Neutrophil elastase (NE) inhibitor

Chronic obstructive pulmonary disease
Bronchiectasis
Cystic fibrosis

Oral
(Low)

AZD0530 (PDF - 111KB)
Saracatinib

Src tyrosine kinase family inhibitor

Solid tumors

Oral
(Yes)

AZD1775 (PDF - 104KB)

WEE1 G2 checkpoint kinase inhibitor

Advanced solid tumors

Oral
(Unknown)

+CNS penetrant: Yes, no,maybe, low or unknown.

Last updated: 11-08-2017
▲ Back to top